Moderna
MRNA
#270
Rank
NZ$160.06 B
Marketcap
NZ$400.93
Share price
14.21%
Change (1 day)
755.22%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Moderna (MRNA) - Cash on Hand

Cash on Hand as of June 2026 : NZ$9.15 Billion

According to Moderna 's latest financial reports the company has NZ$9.15 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Moderna - Cash on Hand chart (from 2017 to 2026)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31NZ$10.01 B-19.62%
2024-12-31NZ$12.45 B-8.45%
2023-12-31NZ$13.60 B-12.76%
2022-12-31NZ$15.59 B-0.69%
2021-12-31NZ$15.70 B145.91%
2020-12-31NZ$6.38 B289.94%
2019-12-31NZ$1.63 B-27.79%
2018-12-31NZ$2.26 B113.07%
2017-12-31NZ$1.06 B-30.31%
2016-12-31NZ$1.52 B

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Johnson & Johnson
JNJ
NZ$36.98 B 304.01%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$13.70 B 49.67%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Merck
MRK
NZ$12.72 B 38.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ$0.11 B-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ$1.81 M-99.98%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$5.89 B-35.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Arrowhead Pharmaceuticals
ARWR
NZ$2.85 B-68.82%๐Ÿ‡บ๐Ÿ‡ธ USA